We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03323398
Recruitment Status : Terminated (This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.)
First Posted : October 27, 2017
Last Update Posted : July 11, 2022
Information provided by (Responsible Party):
ModernaTX, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : August 18, 2021
Actual Study Completion Date : August 18, 2021
Certification/Extension First Submitted : July 7, 2022